Harvest Declares Big Pharma Split Corp. January 2026 Distribution

Harvest Portfolios Group Inc. has announced the monthly cash distribution for Big Pharma Split Corp. for January 2026, declaring a payment of $0.1031 per Class A share (PRM:TSX). This distribution is scheduled to be paid on February 6, 2026, to shareholders recorded by the close of business on January 30, 2026.

Founded in 2009, Harvest operates as an independent Canadian Investment Fund Manager, currently overseeing over $10 billion in assets for Canadian investors. The firm’s investment strategy focuses on building and preserving wealth through long-term ownership of high-quality businesses. Their ETFs offer a range of strategies, including covered call options across various asset classes such as Equity, Enhanced, Premium Yield, Fixed Income, Multi-Asset, Specialty, Digital Assets, and Single Stock ETFs.

For those needing further information regarding the distribution or the company, Harvest has provided multiple contact options. Interested parties can visit their website at www.harvestportfolios.com, send an email to info@harvestetfs.com, or call their toll-free number at 1-866-998-8298. Media inquiries can be directed to Caroline Grimont, the Chief Marketing Officer, via email at cgrimont@HarvestETFs.com.

It's essential for investors to be aware that brokerage fees may apply when buying or selling shares of the fund. The share prices can fluctuate, leading to possible differences between purchase prices and the current net asset value. Additionally, investment funds carry associated ongoing fees and expenses and are not guaranteed, with their value subject to change. For a comprehensive understanding of the investment fund, detailed disclosure documents are available.

The recent declaration by Harvest Portfolios Group Inc. regarding a monthly cash distribution of $0.1031 for each class A share of Big Pharma Split Corp. (PRM:TSX) for January 2026 offers investors a consistent income opportunity within a volatile market environment. This distribution, payable on February 6, 2026, highlights Harvest's commitment to providing returns to its shareholders, which is critical in the current economic climate characterized by interest rate fluctuations and inflationary pressures.

Investors looking at PRM:TSX should consider Harvest's strategic positioning within the healthcare sector, which often serves as a defensive investment. The pharmaceutical industry typically exhibits resilience during economic downturns, fueled by constant demand for healthcare products and services. With Harvest managing over $10 billion in assets, their robust experience adds another layer of confidence for potential investors.

The $0.1031 monthly distribution translates to an annual yield of approximately 12.37%, which is attractive compared to traditional fixed-income securities. This yield could appeal to income-focused investors seeking better returns than what is currently offered by savings accounts or government bonds. However, investors must be mindful of the risks associated with mutual funds and investment vehicles, including market volatility and management costs.

Prospective investors are advised to consider the long-term fundamentals of the Big Pharma sector alongside Harvest's investment strategies. Understanding these dynamics is essential in assessing the risk-reward proposition. Moreover, for those interested in diversifying their portfolios, Harvest's broad range of ETFs that adopt varying strategies—including covered call strategies—may offer additional pathways to enhance yield.

In summary, the January 2026 distribution underscores Harvest's focus on generating shareholder value. However, potential investors should remain vigilant about the inherent risks while capitalizing on the income opportunity presented by Big Pharma Split Corp.